"I believe research is an integral part of our scientific progress and I would like to contribute my share and gain a greater appreciation for science. My goal for the academic year is for my research to be recognized by the scientific community."
Applied Physiology and Kinesiology
Bone metabolism, Endocrinology, Sarcopenia.
Academic and Other Awards
- University Scholars Program Scholarship (2011-2012)
- UF Gold Scholarship
- Dean's List (2008)
- College of Health and Human Performance Ambassadors
- College of Health and Human Performance Mentee Program Heal the World
Interface Peru Mission Trip, Group Leader March of Dimes.
Hobbies and Interests
- Basketball, football, exercising, and Harry Potter.
The relationship between Sclerostin, Estrogen, and Testosterone Serum Concentrations in Men over Age 60
Loss of bone mineral density (BMD) is a problem in aging men . Several therapies have been developed to counteract the decrease in BMD in aging men including the administration of testosterone and estrogen. Traditionally, testosterone was thought to be the dominant hormone in bone metabolism for men; although estrogen also has an important role in the maintenance of BMD in men. Testosterone and estrogen have shown positive effects on BMD, however, the mechanism(s) for these effects remain unknown. Sclerostin is a potent antagonist to Wnt signaling and therefore causes increased bone resorption. Studies have shown that the inhibition of sclerostin has stimulated bone formation and increased bone strength and bone mass in aged male rats. Sclerosteosis, a genetic condition in which the gene encoding sclerostin is improperly spliced, leads to excessive bone growth. Research have shown that inhibition of sclerostin by sclerostin antibodies has demonstrated to have the most powerful anabolic effect on bone. With increasing age, there is a decrease in bioavailable testosterone and estrogen leading to increased bone resorption in aging males; suggesting that testosterone and/or estrogen may affect sclerostin. However, the relationship between sclerostin and the endogenous sex steroids is unknown. Determining the relationship between sclerostin and the sex steroids may provide additional information supporting hormone replacement therapy in aged men. Furthermore, evaluation of this relationship may provide information to improve the treatment of osteoporosis by aiding in the understanding of the roles of sclerostin, estrogen, and testosterone in regulating bone formation and bone resorption. The purpose of this study is to determine whether there is a relationship between the serum concentrations of sclerostin, 17β-estradiol, and testosterone in men over age 60. This will be determined by analyzing blood samples collected from 243 men between the ages of 60-93.